e
Small moleculeexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2018 (NCT03994484)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06356610 | N/A | Feb 6, 2024 | altria, Celerion |
| NCT06208072 | N/A | Sep 1, 2023 | Aristotle University of Thessaloniki, University of Athens |
| NCT05117658 | Phase 2 | Nov 30, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT05072535 | Phase 1 | Oct 8, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT04787328 | Phase 2 | Jul 13, 2021 | Shijiazhuang Pharma Group (CSPC) |
| NCT04784520 | Phase 2 | Jun 22, 2021 | Shijiazhuang Pharma Group (CSPC), Sun Yat-Sen University |
| NCT03994484 | Phase 1 | Apr 1, 2018 | Shijiazhuang Pharma Group (CSPC) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shijiazhuang Pharma Group (CSPC) | For profit | 5 | 5 | 2 | 2018 |
| altria | For profit | 1 | 1 | 1 | 2024 |
| Aristotle University of Thessaloniki | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Celerion | For profit | 1 | 0 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Athens | Academic/Hospital | 1 | 0 | 1 | 2023 |
6 organizations
Page 1 / 1